Indications
Namuscla is indicated for the symptomatic treatment of myotonia in adult patients with non-dystrophic myotonic disorders.
Composition
- Active substance
- Mexiletine hydrochloride
- International name (INN)
- Mexiletine
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Namuscla
- Active substance
- Mexiletine hydrochloride
- ATC code
- C01BB02
- Therapeutic area
- Myotonic Disorders
- Marketing authorisation holder
- Lupin Europe GmbH
- Status
- Authorised